| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 1117.39% | HC Wainwright & Co. | → $14 | Reiterates | Buy → Buy |
| 06/05/2023 | 595.65% | EF Hutton | → $8 | Reiterates | Buy → Buy |
| 05/16/2023 | 1117.39% | HC Wainwright & Co. | → $14 | Reiterates | Buy → Buy |
| 04/26/2023 | 1117.39% | HC Wainwright & Co. | → $14 | Reiterates | → Buy |
| 04/24/2023 | 943.48% | Mizuho | → $12 | Reiterates | → Buy |
| 04/17/2023 | 595.65% | EF Hutton | → $8 | Maintains | Buy |
| 03/31/2023 | 595.65% | EF Hutton | → $8 | Reiterates | → Buy |
| 03/31/2023 | 1117.39% | HC Wainwright & Co. | → $14 | Reiterates | → Buy |
| 03/29/2023 | 595.65% | EF Hutton | → $8 | Initiates Coverage On | → Buy |
| 11/11/2022 | 160.87% | B. Riley Securities | $9 → $3 | Downgrades | Buy → Neutral |
| 08/30/2022 | 1117.39% | HC Wainwright & Co. | → $14 | Initiates Coverage On | → Buy |
| 01/24/2022 | 682.61% | B. Riley Securities | $19 → $9 | Maintains | Buy |
| 08/24/2021 | 943.48% | Mizuho | → $12 | Initiates Coverage On | → Buy |
| 08/23/2021 | 1552.17% | B. Riley Securities | → $19 | Initiates Coverage On | → Buy |
What is the target price for IN8bio (INAB)?
The latest price target for IN8bio (NASDAQ: INAB) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $14.00 expecting INAB to rise to within 12 months (a possible 1117.39% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for IN8bio (INAB)?
The latest analyst rating for IN8bio (NASDAQ: INAB) was provided by HC Wainwright & Co., and IN8bio reiterated their buy rating.
When is the next analyst rating going to be posted or updated for IN8bio (INAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IN8bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IN8bio was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
Is the Analyst Rating IN8bio (INAB) correct?
While ratings are subjective and will change, the latest IN8bio (INAB) rating was a reiterated with a price target of $0.00 to $14.00. The current price IN8bio (INAB) is trading at is $1.15, which is within the analyst's predicted range.